Dr. Jennifer Park
Chief Medical Officer
Biotechnology is fundamentally a long-term game. The journey from initial discovery to approved therapy can take 15 years or more, requiring multiple rounds of funding, countless setbacks, and unwavering commitment.
The Patient Capital Advantage
Not all capital is created equal. In biotech, patient capital—investors willing to support companies through the long, uncertain journey of drug development—is essential. This means understanding that progress isn't always linear and that setbacks are part of the process.
The most successful biotech companies are built by teams that understand this reality. They plan for the long term, build robust scientific foundations, and maintain focus even when the path forward isn't clear.
Lessons from the Field
We've seen companies that looked promising in early stages but failed because they lacked the capital structure to see through the inevitable challenges. We've also seen companies that seemed to struggle early but ultimately succeeded because they had the right support.
"The difference between success and failure in biotech often comes down to having investors who understand the science and are committed for the long haul."
At CGV, we're committed to being that kind of partner. We understand that building transformative therapies takes time, and we're here for the entire journey.